Overview

Bioavailability of LY03004 and Risperdal® Consta®

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

This study is to assess the bioavailability of LY03004 compared to Risperdal Consta as well as the evaluate the safety and tolerability and preliminary efficacy of LY03004 with repeat injections

Phase:

Phase 1

Details

Lead Sponsor:

Luye Pharma Group Ltd.

Treatments:

Risperidone